
Feb 23 (Reuters) - Armata Pharmaceuticals Inc ARMP.A:
ARMATA PHARMACEUTICALS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) DESIGNATION FOR AP-SA02
ARMATA: PLANS TO ADVANCE AP-SA02 INTO PHASE 3 SUPERIORITY STUDY IN COMPLICATED S. AUREUS BACTEREMIA, ANTICIPATED TO INITIATE IN SECOND HALF OF 2026